Watches safety of Alhemo in Japanese people with haemophilia with inhibitors
Studies how Alhemo, given as routinely prescribed, works in people with haemophilia A or B.
Plain-language title generated from the registry record
Registry title: Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Key facts
- Where
- Aomori, Fukuoka, Hokkaido, Kagoshima, Kanagawa, Kitakyusyu-shi, Fukuoka, Okinawa, Tokyo, and Toshima City, JapanSee the 11 sites
Where in Japan
- Mutsu general hospital_PediatricsAomori, JapanNo longer taking part
- Kyushu university hospital_PediatricsFukuoka, JapanNo longer taking part
- Sapporo Tokushukai Hospital_PediatricsHokkaido, JapanNo longer taking part
- Kagoshima City Hospital_PediatricsKagoshima, JapanNo longer taking part
- St. Marianna University School of Medicine Hospital_PediatricsKanagawa, JapanNo longer taking part
- Hospital of the University of Occupational And Environmental Health Japan_PediatricsKitakyusyu-shi, Fukuoka, JapanNo longer taking part
- Nanbu Medical Center & Children's Medical Center_Hematology and OncologyOkinawa, JapanNo longer taking part
- University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and RheumatologyOkinawa, JapanNo longer taking part
- Ogikubo Hospital_Blood CoagulationTokyo, JapanNo longer taking part
- Tokyo Medical University HospitalTokyo, JapanNo longer taking part
- Toshima CityToshima City, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT06285071
- Record updated
- 15 June 2026
- Original description
The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.Read full original descriptionShow less
A Multi-centre, Open-label, Single-arm, Non-interventional Post-marketing Study to Investigate Safety and Clinical Parameters of Alhemo® Under Routine Clinical Practice in Japan
The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.
Inclusion: Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol); The decision to initiate treatment with commercially available Alhemo® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study; Male or female patients, regardless of age; Diagnosis with HAwI/HBwI.
Exclusion: Previous participation in this study. Participation is defined as having given informed consent in this study.